BELLEVUE, Wash., Oct. 14, 2016 -- Blucora, Inc. (NASDAQ:BCOR), a leading provider of technology-enabled financial solutions to consumers, small businesses and tax professionals, today announced that effective on October 14, 2016 it granted an equity award to Pamela Turay, Blucora’s new Chief Human Resources Officer. Turay was appointed as Chief Human Resources Officer effective October 3, 2016 and reports directly to Blucora President and Chief Executive Officer, John Clendening.
With more than 20 years business experience in human capital leadership, Ms. Turay will lead Blucora’s efforts in the design, development, and execution of human resources strategies and initiatives, including talent management, learning and development, compensation and benefits, performance management, succession planning, organizational transformation, and change management. Most recently, Ms. Turay served as Senior Vice President of Human Resources and Development for Jackson Hewitt Tax Service. Previously, she also served in roles such as Chief People Officer for Gibson Guitar Corp, and Senior Vice President Human Resources and Corporate Sales, and Vice President Talent Management and Development at Harry & David.
The awards were approved by the independent compensation committee of Blucora’s Board of Directors and were granted as an inducement to Ms. Turay entering into employment with Blucora. The awards were granted under Blucora’s 2016 Equity Inducement Plan, as amended, which Blucora’s board of directors adopted to facilitate the granting of equity awards to new employees in accordance with NASDAQ Listing Rule 5635(c)(4).
The inducement awards consist of restricted stock units, or RSUs, for an aggregate of 14,347 shares of Blucora common stock and stock options to purchase an aggregate of 103,782 shares of Blucora common stock. Subject to continued employment with Blucora, the RSUs will vest over a three-year period, with 33 1/3rd of the RSUs vesting on the first anniversary of the vesting commencement date, which is October 3, 2016, and the remainder vesting in equal six-month installments over the two years thereafter. The stock options have an exercise price of $11.50 per share, the closing price per share of Blucora common stock as reported by NASDAQ on October 14, 2016, the date of grant. The options have a seven-year term and, subject to continued employment with Blucora, will vest over a three-year period, with 33 1/3rd of the options vesting on the first anniversary of the vesting commencement date, which is October 3, 2016, and the remainder vesting in equal six-month installments over the two years thereafter.
About Blucora®
Blucora, Inc. (NASDAQ:BCOR) is a leading provider of technology-enabled financial solutions to consumers, small businesses and tax professionals. Our products and services in tax preparation and wealth management, through TaxAct and HD Vest, help consumers manage their financial lives. TaxAct is an affordable digital tax preparation solution for individuals, business owners and tax professionals. HD Vest Financial Services® supports an independent network of tax professionals who provide comprehensive financial planning solutions. For more information on Blucora or its businesses, please visit www.blucora.com.
Contact Stacy Ybarra, 425-709-8127 Blucora, Inc. [email protected]


FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Italy Fines Apple €98.6 Million Over App Store Dominance
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 



